CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
This pilot study evaluated CPX-351 in adults with newly diagnosed, favourable-intermediate risk, FLT3-ITD-negative AML. Twenty patients received CPX-351 for induction, with six also receiving gemtuzumab ozogamicin (GO). The complete response rate was 95%, with 42% achieving flow-based minimal residual disease (MRD) negativity post-induction. The 18-month leukaemia-free and overall survival estimates were 80% and 95% respectively. Adding GO appeared safe without prolonged cytopenias. Subclinical cardiotoxicity was observed in 25% of patients. The study demonstrated CPX-351's feasibility, with response and MRD-negativity rates comparable to standard '7 + 3' induction.
Authors
- Ofir Wolach (ORCID: https://orcid.org/0000-0002-8662-0707)
- Baher Krayem
- Yishai Ofran (ORCID: https://orcid.org/0000-0002-5521-1337)
- Emmanuel Benayoun (ORCID: https://orcid.org/0000-0002-3198-6656)
- Jacob M. Rowe (ORCID: https://orcid.org/0000-0002-2016-2918)
- Chezi Ganzel (ORCID: https://orcid.org/0000-0002-1722-4807)
- Yakir Moshe (ORCID: https://orcid.org/0009-0003-3810-0218)
- Neta Dor
- Eti Broide
- Avraham Frisch
Institutions
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Rabin Medical Center (IL)
- Rambam Health Care Campus (IL)
- Shaare Zedek Medical Center (IL)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1111/bjh.19967
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Jazz Pharmaceuticals